Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FENC
stocks logo

FENC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.21M
+79.31%
0.033
-155.55%
17.48M
+99.78%
0.122
-406.25%
19.38M
+100.83%
0.190
-272.73%
Estimates Revision
The market is revising No Change the revenue expectations for Fennec Pharmaceuticals Inc. (FENC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -13.56%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+98.36%
In Past 3 Month
Stock Price
Go Down
down Image
-13.56%
In Past 3 Month
Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.780
sliders
Low
13.00
Averages
13.00
High
13.00
Current: 7.780
sliders
Low
13.00
Averages
13.00
High
13.00
Craig-Hallum
Chase Knickerbocker
Buy
maintain
$13 -> $14
2025-08-15
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$13 -> $14
2025-08-15
maintain
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Fennec to $14 from $13 and keeps a Buy rating on the shares following quarterly results. The firm notes that legal expenses and one-time PSUs tied to 2025 goals drove elevated opex, but management expects material expense reduction in the second half of the year. Growth in the AYA population for Pedmark drove account expansion, with 14 new accounts added in the quarter. Internationally, Pedmarqsi launched in Germany and the U.K., with early royalty contributions from Norgine expected to ramp through the year. Additional EU launches are planned for the first half of 2026, and Japan data expected in Q4 bring potential partnership discussions for Japan rights and non-dilutive capital, Craig-Hallum adds.
Craig-Hallum
Buy
maintain
$12 -> $13
2025-05-14
Reason
Craig-Hallum
Price Target
$12 -> $13
2025-05-14
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Fennec to $13 from $12 and keeps a Buy rating on the shares following the company's Q1 earnings beat. The results for Q1 are near the breakeven amount for revenue, the firm notes. Craig-Hallum says that continued wins at potential major accounts, along with improved adherence to treatment from investments in the commercial team, could start to inflect the AYA channel.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$13
2025-03-11
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$13
2025-03-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$13
2024-12-17
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$13
2024-12-17
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fennec Pharmaceuticals Inc (FENC.O) is 16.10, compared to its 5-year average forward P/E of 4.66. For a more detailed relative valuation and DCF analysis to assess Fennec Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
4.66
Current PE
16.10
Overvalued PE
54.36
Undervalued PE
-45.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
3.92
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.58
Undervalued EV/EBITDA
-8.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.14
Current PS
0.00
Overvalued PS
54.91
Undervalued PS
-20.63
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 204.72% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 204.72% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FENC News & Events

Events Timeline

(ET)
2025-12-02
07:11:00
Fennec Pharmaceuticals' PEDMARK Trial Shows Significant Hearing Loss Reduction
select
2025-11-19 (ET)
2025-11-19
07:15:34
Fennec Successfully Repays All Outstanding Debt
select
2025-11-14 (ET)
2025-11-14
06:31:07
Fennec's 4.7M Share Spot Secondary Offering Set at $7.50
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Benzinga
PinnedPedmark Shows Promising Results in Japan Study — Reduced Hearing Loss with Equivalent Cancer-Fighting Efficacy

  • Study Results: Fennec Pharmaceuticals announced positive topline results from the Phase 2/3 STS-J01 trial of Pedmark, showing reduced rates of cisplatin-induced ototoxicity in pediatric patients, with only 24% and 16% experiencing hearing loss compared to higher rates in previous trials.

  • Safety and Efficacy: The study confirmed that Pedmark does not interfere with the antitumor activity of cisplatin, maintaining a high tumor response rate of approximately 95%, and was well-tolerated with no adverse events attributed to the drug.

  • Future Plans: Fennec intends to pursue regulatory registration for Pedmark in Japan and explore potential partnerships or licensing opportunities, with full study results to be presented in a scientific forum and submitted for publication.

  • Market Reaction: Following the announcement, Fennec Pharmaceuticals' stock experienced a slight decline of 0.78%, trading at $7.85.

[object Object]
Preview
9.0
12-02Globenewswire
Fennec Pharmaceuticals' PEDMARK® Significantly Reduces Hearing Loss in Children
  • Clinical Trial Success: Fennec Pharmaceuticals' PEDMARK® demonstrated a significant reduction in hearing loss among 27 patients aged 3-18 in Japan's STS-J01 trial, with only 24% and 16% experiencing ototoxicity, compared to 56%-63% in traditional chemotherapy, highlighting its effectiveness in reducing ototoxicity.
  • Maintained Antitumor Activity: The study confirmed a high tumor response rate of approximately 95% with PEDMARK®, showing no adverse effects on cisplatin's antitumor efficacy, which ensures both safety and effectiveness in treatment.
  • Market Registration Plans: Fennec intends to pursue registration for PEDMARK® in Japan while exploring partnering or licensing opportunities, demonstrating the company's commitment to addressing unmet medical needs in the region.
  • Enhanced Global Impact: The trial results further solidify PEDMARK®'s clinical evidence base globally, enhancing its potential for application across various countries and tumor types, which may lead to broader market opportunities for the company.
[object Object]
Preview
9.0
12-02Newsfilter
Fennec Pharmaceuticals' PEDMARK® Significantly Reduces Hearing Loss in Children
  • Clinical Trial Success: Fennec Pharmaceuticals' PEDMARK® demonstrated a significant reduction in hearing loss, with only 24% and 16% of 27 patients aged 3-18 experiencing ototoxicity, compared to 56%-63% in traditional chemotherapy, highlighting its effectiveness in reducing ototoxicity.
  • Maintained Antitumor Activity: The study confirmed a 95% tumor response rate with PEDMARK® used alongside cisplatin, showing no interference with cisplatin's antitumor activity, thus ensuring both safety and efficacy in treatment.
  • Market Registration Plans: Fennec intends to pursue registration for PEDMARK® in Japan while exploring partnering or licensing opportunities, aiming to expand its influence in the Asia-Pacific market to meet the urgent need for ototoxicity prevention drugs.
  • Enhanced Patient Welfare: The findings provide hope for pediatric cancer patients in Japan, indicating that PEDMARK® can protect hearing without compromising cisplatin's efficacy, thereby improving quality of life and addressing unmet medical needs.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fennec Pharmaceuticals Inc (FENC) stock price today?

The current price of FENC is 7.78 USD — it has increased 2.77 % in the last trading day.

arrow icon

What is Fennec Pharmaceuticals Inc (FENC)'s business?

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

arrow icon

What is the price predicton of FENC Stock?

Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fennec Pharmaceuticals Inc (FENC)'s revenue for the last quarter?

Fennec Pharmaceuticals Inc revenue for the last quarter amounts to 12.46M USD, increased 78.69 % YoY.

arrow icon

What is Fennec Pharmaceuticals Inc (FENC)'s earnings per share (EPS) for the last quarter?

Fennec Pharmaceuticals Inc. EPS for the last quarter amounts to -0.02 USD, decreased -90.48 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fennec Pharmaceuticals Inc (FENC)'s fundamentals?

The market is revising No Change the revenue expectations for Fennec Pharmaceuticals Inc. (FENC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -13.56%.
arrow icon

How many employees does Fennec Pharmaceuticals Inc (FENC). have?

Fennec Pharmaceuticals Inc (FENC) has 29 emplpoyees as of December 05 2025.

arrow icon

What is Fennec Pharmaceuticals Inc (FENC) market cap?

Today FENC has the market capitalization of 265.71M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free